[
  {
    "title": "凯莱英(002821.SZ)拟推2022年员工持股计划",
    "href": "http://stock.jrj.com.cn/2022/11/17185537147660.shtml",
    "datetime": "2022-11-17 18:55:46",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：拟变更回购股份用途为用于后续实施员工持股计划及注销减少注册资本",
    "href": "http://stock.jrj.com.cn/2022/11/17185537147662.shtml",
    "datetime": "2022-11-17 18:55:13",
    "code": "002821"
  },
  {
    "title": "港股异动 | 凯莱英AH股齐涨 累计斥资近8亿元回购A股",
    "href": "http://stock.jrj.com.cn/2022/11/11103937130244.shtml",
    "datetime": "2022-11-11 10:39:06",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：回购完成 已累计回购1.5271%股份",
    "href": "http://stock.jrj.com.cn/2022/11/10174337128203.shtml",
    "datetime": "2022-11-10 17:43:27",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)前三季度预盈约27亿元、同比增长约290%",
    "href": "http://stock.jrj.com.cn/2022/10/23183837076007.shtml",
    "datetime": "2022-10-23 18:38:24",
    "code": "002821"
  },
  {
    "title": "【龙虎榜】凯莱英10月14日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/10/14180237056722.shtml",
    "datetime": "2022-10-14 18:02:22",
    "code": "002821"
  },
  {
    "title": "凯莱英：拟40亿-50亿元投建生物医药研发生产一体化基地",
    "href": "http://stock.jrj.com.cn/2022/09/26190037022574.shtml",
    "datetime": "2022-09-26 19:00:50",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：拟投资40-50亿元在泰兴建生物医药研发生产一体化基地项目",
    "href": "http://stock.jrj.com.cn/2022/09/26185337022569.shtml",
    "datetime": "2022-09-26 18:53:12",
    "code": "002821"
  },
  {
    "title": "凯莱英：拟40-50亿元投建生物医药研发生产一体化基地项目",
    "href": "http://stock.jrj.com.cn/2022/09/26183537022424.shtml",
    "datetime": "2022-09-26 18:35:04",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)9月19日耗资4921万元回购34.44万股A股",
    "href": "http://stock.jrj.com.cn/2022/09/19211037006220.shtml",
    "datetime": "2022-09-19 21:10:06",
    "code": "002821"
  },
  {
    "title": "凯莱英：已回购5.47亿元 占A股总股本1%",
    "href": "http://stock.jrj.com.cn/2022/09/19184737005675.shtml",
    "datetime": "2022-09-19 18:47:22",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：累计耗资5.47亿元回购1.0003%股份",
    "href": "http://stock.jrj.com.cn/2022/09/19165537005101.shtml",
    "datetime": "2022-09-19 16:55:42",
    "code": "002821"
  },
  {
    "title": "网友自称“爆仓”黑天鹅凯莱英！两度刷屏，大跌晒惨成流量密码，券商究竟如何防控客户爆仓",
    "href": "http://stock.jrj.com.cn/2022/09/15072836995806.shtml",
    "datetime": "2022-09-15 07:28:35",
    "code": "002821"
  },
  {
    "title": "突遭黑天鹅，“公募一姐”抄底凯莱英早了点",
    "href": "http://stock.jrj.com.cn/2022/09/14170136994384.shtml",
    "datetime": "2022-09-14 17:01:30",
    "code": "002821"
  },
  {
    "title": "【龙虎榜】凯莱英9月13日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/09/13180036991774.shtml",
    "datetime": "2022-09-13 18:00:33",
    "code": "002821"
  },
  {
    "title": "【龙虎榜】凯莱英9月13日成交明细(dev)",
    "href": "http://stock.jrj.com.cn/2022/09/13180036991761.shtml",
    "datetime": "2022-09-13 18:00:06",
    "code": "002821"
  },
  {
    "title": "凯莱英跌停 四机构合计卖出1.35亿元",
    "href": "http://stock.jrj.com.cn/2022/09/13173436991628.shtml",
    "datetime": "2022-09-13 17:34:30",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：26.796万股限制性股票将解除限售上市流通",
    "href": "http://stock.jrj.com.cn/2022/09/05212136975154.shtml",
    "datetime": "2022-09-05 21:21:15",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)9月5日首次回购54.97万股",
    "href": "http://stock.jrj.com.cn/2022/09/05173436974225.shtml",
    "datetime": "2022-09-05 17:34:45",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)半年度净利润17.4亿元 同比增长305.31%",
    "href": "http://stock.jrj.com.cn/2022/08/25210636937387.shtml",
    "datetime": "2022-08-25 21:06:01",
    "code": "002821"
  },
  {
    "title": "凯莱英：上半年净利润17.4亿元 同比增长305.31%",
    "href": "http://stock.jrj.com.cn/2022/08/25180236936421.shtml",
    "datetime": "2022-08-25 18:02:56",
    "code": "002821"
  },
  {
    "title": "股价跳空放量涨逾9%！回购成凯莱英的“护盘”良药？",
    "href": "http://stock.jrj.com.cn/2022/08/05101736872840.shtml",
    "datetime": "2022-08-05 10:17:35",
    "code": "002821"
  },
  {
    "title": "溢价上限80%回购，CRO龙头大手笔能否让坐在过山车上的投资人重拾信心？",
    "href": "http://stock.jrj.com.cn/2022/08/04185936871128.shtml",
    "datetime": "2022-08-04 18:59:35",
    "code": "002821"
  },
  {
    "title": "凯莱英：拟以4亿元-8亿元回购股份",
    "href": "http://stock.jrj.com.cn/2022/08/03173236867199.shtml",
    "datetime": "2022-08-03 17:32:15",
    "code": "002821"
  },
  {
    "title": "前沿生物(688221.SH)：拟与凯莱英在新冠3CL蛋白酶抑制剂产品FB2001建立战略合作",
    "href": "http://stock.jrj.com.cn/2022/07/14230036813367.shtml",
    "datetime": "2022-07-14 23:00:56",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)半年度扣非净利润预增359.24%-386.31%",
    "href": "http://stock.jrj.com.cn/2022/07/14221736813192.shtml",
    "datetime": "2022-07-14 22:17:17",
    "code": "002821"
  },
  {
    "title": "前沿生物：拟与凯莱英在新冠3CL蛋白酶抑制剂产品FB2001建立战略合作",
    "href": "http://stock.jrj.com.cn/2022/07/14173936811814.shtml",
    "datetime": "2022-07-14 17:39:45",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)2021年度权益分派10转4派8元、股权登记日为7月20日",
    "href": "http://stock.jrj.com.cn/2022/07/13220536809084.shtml",
    "datetime": "2022-07-13 22:05:56",
    "code": "002821"
  },
  {
    "title": "【龙虎榜】凯莱英6月24日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/06/24180136757327.shtml",
    "datetime": "2022-06-24 18:01:44",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)遭FMR LLC减持6.8万股",
    "href": "http://stock.jrj.com.cn/2022/06/21071436744691.shtml",
    "datetime": "2022-06-21 07:14:46",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：聘任XINHUI HU为公司首席技术官兼首席商务官",
    "href": "http://stock.jrj.com.cn/2022/06/20210236744303.shtml",
    "datetime": "2022-06-20 21:02:41",
    "code": "002821"
  },
  {
    "title": "凯莱英聘任XINHUI HU为公司首席技术官（CTO） 2021年度公司净利10.69亿",
    "href": "http://stock.jrj.com.cn/2022/06/20191036743924.shtml",
    "datetime": "2022-06-20 19:10:46",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)遭摩根大通减持2.14万股",
    "href": "http://stock.jrj.com.cn/2022/06/09063736714390.shtml",
    "datetime": "2022-06-09 06:37:00",
    "code": "002821"
  },
  {
    "title": "港股异动 | 凯莱英涨10% 获摩根大通增持4.24万股",
    "href": "http://stock.jrj.com.cn/2022/06/08105036711640.shtml",
    "datetime": "2022-06-08 10:50:56",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)获摩根大通增持4.24万股",
    "href": "http://stock.jrj.com.cn/2022/06/07074636707675.shtml",
    "datetime": "2022-06-07 07:46:31",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)遭FMR LLC减持10万股",
    "href": "http://stock.jrj.com.cn/2022/06/07073936707639.shtml",
    "datetime": "2022-06-07 07:39:34",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)遭FIDELITY INVESTMENT TRUST减持6.3万股",
    "href": "http://stock.jrj.com.cn/2022/06/07073336707640.shtml",
    "datetime": "2022-06-07 07:33:21",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)获摩根大通增持7.73万股",
    "href": "http://stock.jrj.com.cn/2022/05/27070536683059.shtml",
    "datetime": "2022-05-27 07:05:15",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)遭FMR LLC减持14.54万股",
    "href": "http://stock.jrj.com.cn/2022/05/26072036679548.shtml",
    "datetime": "2022-05-26 07:20:52",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)遭FMR LLC减持6.54万股",
    "href": "http://stock.jrj.com.cn/2022/05/23070136668793.shtml",
    "datetime": "2022-05-23 07:01:09",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)遭摩根大通减持6.74万股",
    "href": "http://stock.jrj.com.cn/2022/05/19071536660713.shtml",
    "datetime": "2022-05-19 07:15:03",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)遭FMR LLC减持22.93万股",
    "href": "http://stock.jrj.com.cn/2022/05/17074036653639.shtml",
    "datetime": "2022-05-17 07:40:16",
    "code": "002821"
  },
  {
    "title": "港股异动 | 凯莱英跌5% FMR LLC两日减持逾20万股",
    "href": "http://stock.jrj.com.cn/2022/05/03104336541250.shtml",
    "datetime": "2022-05-03 10:43:26",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)遭FMR LLC减持4.67万股",
    "href": "http://stock.jrj.com.cn/2022/04/28065036489493.shtml",
    "datetime": "2022-04-28 06:50:16",
    "code": "002821"
  },
  {
    "title": "凯莱英港股股价盘中创历史新低，遭FMR LLC减持19.83万股",
    "href": "http://stock.jrj.com.cn/2022/04/25153536463152.shtml",
    "datetime": "2022-04-25 15:35:07",
    "code": "002821"
  },
  {
    "title": "港股异动 | 凯莱英跌7% 遭FMR LLC减持19.83万股",
    "href": "http://stock.jrj.com.cn/2022/04/25140136461908.shtml",
    "datetime": "2022-04-25 14:01:45",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)遭FMR LLC减持19.83万股",
    "href": "http://stock.jrj.com.cn/2022/04/25063536455265.shtml",
    "datetime": "2022-04-25 06:35:41",
    "code": "002821"
  },
  {
    "title": "凯莱英第一季度总营收同比增长165.28%，多项业务增长迅速",
    "href": "http://stock.jrj.com.cn/2022/04/20172936410754.shtml",
    "datetime": "2022-04-20 17:29:42",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：7.04万股限制性股票可解锁",
    "href": "http://stock.jrj.com.cn/2022/04/20165036410335.shtml",
    "datetime": "2022-04-20 16:50:56",
    "code": "002821"
  },
  {
    "title": "【龙虎榜】凯莱英4月13日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/04/13180236325355.shtml",
    "datetime": "2022-04-13 18:02:55",
    "code": "002821"
  },
  {
    "title": "凯莱英跌停 四机构合计卖出1.8亿元",
    "href": "http://stock.jrj.com.cn/2022/04/13164436324361.shtml",
    "datetime": "2022-04-13 16:44:05",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)4月20日举行董事会会议审批一季度业绩",
    "href": "http://stock.jrj.com.cn/2022/04/06170236263145.shtml",
    "datetime": "2022-04-06 17:02:34",
    "code": "002821"
  },
  {
    "title": "凯莱英2021年净利10.69亿同比增长48.08% 董事长HAOHONG薪酬212.98万",
    "href": "http://stock.jrj.com.cn/2022/03/31095236229671.shtml",
    "datetime": "2022-03-31 09:52:56",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)2021年度净利升48.08%至10.69亿元 拟10转4派8元",
    "href": "http://stock.jrj.com.cn/2022/03/30203236205413.shtml",
    "datetime": "2022-03-30 20:32:06",
    "code": "002821"
  },
  {
    "title": "港股异动 | 凯莱英涨5% 子公司凯莱英生物发展拟引入高瓴等外部投资者",
    "href": "http://stock.jrj.com.cn/2022/03/29110636090314.shtml",
    "datetime": "2022-03-29 11:06:49",
    "code": "002821"
  },
  {
    "title": "30倍牛股大动作！拟与高瓴再续前缘：25亿共同增资子公司，加码CDMO赛道",
    "href": "http://stock.jrj.com.cn/2022/03/26132535293452.shtml",
    "datetime": "2022-03-26 13:25:50",
    "code": "002821"
  },
  {
    "title": "高瓴又出手！大手笔布局",
    "href": "http://stock.jrj.com.cn/2022/03/26082135246840.shtml",
    "datetime": "2022-03-26 08:21:50",
    "code": "002821"
  },
  {
    "title": "【晚间公告全知道】凯莱英子公司凯莱英生物发展拟引入高瓴等外部投资者，云南白药年度分红拟10送4派16元",
    "href": "http://stock.jrj.com.cn/2022/03/25220935161677.shtml",
    "datetime": "2022-03-25 22:09:24",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：拟携手高瓴等增资子公司 将其打造为全球CDMO领域的领军企业",
    "href": "http://stock.jrj.com.cn/2022/03/25200235144243.shtml",
    "datetime": "2022-03-25 20:02:33",
    "code": "002821"
  },
  {
    "title": "凯莱英：子公司凯莱英生物发展拟引入高瓴等外部投资者",
    "href": "http://stock.jrj.com.cn/2022/03/25191335135788.shtml",
    "datetime": "2022-03-25 19:13:55",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)3月30日举行董事会会议审批年度业绩",
    "href": "http://stock.jrj.com.cn/2022/03/18170434845680.shtml",
    "datetime": "2022-03-18 17:04:04",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)预计第一季度营业收入增长超150%",
    "href": "http://stock.jrj.com.cn/2022/03/13165534819178.shtml",
    "datetime": "2022-03-13 16:55:52",
    "code": "002821"
  },
  {
    "title": "凯莱英：全资子公司拟1亿元在上海奉贤设立奉贤凯莱英",
    "href": "http://stock.jrj.com.cn/2022/03/07110234536876.shtml",
    "datetime": "2022-03-07 11:02:19",
    "code": "002821"
  },
  {
    "title": "凯莱英全资子公司拟投资1亿设立上海凯莱英生物制药有限公司",
    "href": "http://stock.jrj.com.cn/2022/03/04195234531261.shtml",
    "datetime": "2022-03-04 19:52:07",
    "code": "002821"
  },
  {
    "title": "凯莱英：拟以30亿元投资建设生物药CDMO研发及商业化生产基地",
    "href": "http://stock.jrj.com.cn/2022/03/04180234530890.shtml",
    "datetime": "2022-03-04 18:02:30",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)签订35.42亿元日常经营重大合同",
    "href": "http://stock.jrj.com.cn/2022/02/20163434415255.shtml",
    "datetime": "2022-02-20 16:34:28",
    "code": "002821"
  },
  {
    "title": "凯莱英：签订35.42亿元日常经营重大合同",
    "href": "http://stock.jrj.com.cn/2022/02/20162434415221.shtml",
    "datetime": "2022-02-20 16:24:10",
    "code": "002821"
  },
  {
    "title": "【龙虎榜】凯莱英2月15日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/02/15180234354548.shtml",
    "datetime": "2022-02-15 18:02:54",
    "code": "002821"
  },
  {
    "title": "午评：赛道股反弹创业板指大涨2.64%，CRO概念爆发昭衍新药、凯莱英涨停",
    "href": "http://stock.jrj.com.cn/2022/02/15113234352929.shtml",
    "datetime": "2022-02-15 11:32:32",
    "code": "002821"
  },
  {
    "title": "港股异动丨凯莱英AH均高开 拟收购Snapdragon公司剩余股权 其将成为公司海外研发平台",
    "href": "http://stock.jrj.com.cn/2022/02/14093134339043.shtml",
    "datetime": "2022-02-14 09:31:24",
    "code": "002821"
  },
  {
    "title": "凯莱英：拟收购Snapdragon全部剩余股权 加强公司在小分子CDMO领域研发实力",
    "href": "http://stock.jrj.com.cn/2022/02/11201034325422.shtml",
    "datetime": "2022-02-11 20:10:21",
    "code": "002821"
  },
  {
    "title": "凯莱英拟以自有资金约5794万美元收购Snapdragon股权 收购完成后持股100%",
    "href": "http://stock.jrj.com.cn/2022/02/11195234324696.shtml",
    "datetime": "2022-02-11 19:52:50",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：拟收购Snapdragon公司剩余股权 其将成为公司海外研发平台",
    "href": "http://stock.jrj.com.cn/2022/02/11180234324237.shtml",
    "datetime": "2022-02-11 18:02:13",
    "code": "002821"
  },
  {
    "title": "【龙虎榜】凯莱英2月10日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2022/02/10180234318915.shtml",
    "datetime": "2022-02-10 18:02:12",
    "code": "002821"
  },
  {
    "title": "凯莱英跌逾8% 机构博弈激烈",
    "href": "http://stock.jrj.com.cn/2022/02/10164934318520.shtml",
    "datetime": "2022-02-10 16:49:15",
    "code": "002821"
  },
  {
    "title": "凯莱英：2021年净利同比预增44%-49%",
    "href": "http://stock.jrj.com.cn/2022/01/25180434213093.shtml",
    "datetime": "2022-01-25 18:04:04",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)获摩根大通增持12.67万股",
    "href": "http://stock.jrj.com.cn/2022/01/17074134162345.shtml",
    "datetime": "2022-01-17 07:41:16",
    "code": "002821"
  },
  {
    "title": "凯莱英4名股东合计减持7.27万股 套现合计约2572.13万 第三季度公司净利2.66亿",
    "href": "http://stock.jrj.com.cn/2022/01/07213034135145.shtml",
    "datetime": "2022-01-07 21:30:45",
    "code": "002821"
  },
  {
    "title": "迈瑞医疗、凯莱英、药明康德大跌 ！医药股迎“开门黑” “抄底”还是“快逃”？",
    "href": "http://stock.jrj.com.cn/2022/01/05105134123298.shtml",
    "datetime": "2022-01-05 10:51:31",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)获高盛增持12.1万股",
    "href": "http://stock.jrj.com.cn/2021/12/30074734085149.shtml",
    "datetime": "2021-12-30 07:47:51",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)获FMR LLC增持39.74万股",
    "href": "http://stock.jrj.com.cn/2021/12/24074634056012.shtml",
    "datetime": "2021-12-24 07:46:58",
    "code": "002821"
  },
  {
    "title": "凯莱英（6821.HK/002821.SZ）：项目储备强大，新兴业务打开想象空间",
    "href": "http://stock.jrj.com.cn/2021/12/16131734023993.shtml",
    "datetime": "2021-12-16 13:17:43",
    "code": "002821"
  },
  {
    "title": "IPO | 凯莱英香港上市首日开盘破发，曾遭高瓴资本多次减持",
    "href": "http://stock.jrj.com.cn/2021/12/10132833994207.shtml",
    "datetime": "2021-12-10 13:28:11",
    "code": "002821"
  },
  {
    "title": "“A+H”CDMO领军者来袭，凯莱英（6821.HK/002821.SZ）赴港上市有何看点？",
    "href": "http://stock.jrj.com.cn/2021/12/10102533993746.shtml",
    "datetime": "2021-12-10 10:25:21",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)最终发售价每股388港元 预计12月10日挂牌上市",
    "href": "http://stock.jrj.com.cn/2021/12/09080033988320.shtml",
    "datetime": "2021-12-09 08:00:28",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)发售价定为每股H股388港元 预计12月10日开始交易",
    "href": "http://stock.jrj.com.cn/2021/12/06061333971049.shtml",
    "datetime": "2021-12-06 06:13:34",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：已确定此次境外上市外资股(H股)发行的最终价格为每股388.00港元",
    "href": "http://stock.jrj.com.cn/2021/12/05173933965457.shtml",
    "datetime": "2021-12-05 17:39:58",
    "code": "002821"
  },
  {
    "title": "凯莱英：已确定本次境外上市外资股（H股）发行的最终价格为每股港币388元",
    "href": "http://stock.jrj.com.cn/2021/12/05164033965290.shtml",
    "datetime": "2021-12-05 16:40:12",
    "code": "002821"
  },
  {
    "title": "全球小分子CDMO领跑者，凯莱英(6821.HK/002821.SZ)赴港上市",
    "href": "http://stock.jrj.com.cn/2021/12/02120733954733.shtml",
    "datetime": "2021-12-02 12:07:09",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)拟全球发售1841.54万股 预计12月10日挂牌上市",
    "href": "http://stock.jrj.com.cn/2021/11/30071533941800.shtml",
    "datetime": "2021-11-30 07:15:57",
    "code": "002821"
  },
  {
    "title": "凯莱英(06821.HK)11月30日起招股 发售价每股350-410港元",
    "href": "http://stock.jrj.com.cn/2021/11/30062033940920.shtml",
    "datetime": "2021-11-30 06:20:51",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：拟使用不超12亿元部分闲置募集资金暂补流动资金",
    "href": "http://stock.jrj.com.cn/2021/11/29221333940234.shtml",
    "datetime": "2021-11-29 22:13:46",
    "code": "002821"
  },
  {
    "title": "A股异动丨再签超预期大单 凯莱英(002821.SZ)创历史新高",
    "href": "http://stock.jrj.com.cn/2021/11/29150733937838.shtml",
    "datetime": "2021-11-29 15:07:53",
    "code": "002821"
  },
  {
    "title": "签订27.2亿元大订单，凯莱英今日大涨，股价超500元/股",
    "href": "http://stock.jrj.com.cn/2021/11/29101133936389.shtml",
    "datetime": "2021-11-29 10:11:21",
    "code": "002821"
  },
  {
    "title": "A股异动丨凯莱英高开6.63% 再签逾27亿辉瑞新冠口服药订单",
    "href": "http://stock.jrj.com.cn/2021/11/29093133936057.shtml",
    "datetime": "2021-11-29 09:31:43",
    "code": "002821"
  },
  {
    "title": "凯莱英子公司签27.2亿大单；真视通公司印章、证照已处于失控状态；神力股份股东及高管拟减持不超9.23%股份",
    "href": "http://stock.jrj.com.cn/2021/11/29081433935717.shtml",
    "datetime": "2021-11-29 08:14:35",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)与客户签订新一批《供货合同》 金额约27.20亿元",
    "href": "http://stock.jrj.com.cn/2021/11/28164233929610.shtml",
    "datetime": "2021-11-28 16:42:51",
    "code": "002821"
  },
  {
    "title": "凯莱英：子公司签订新一批《供货合同》 金额约27.2亿元",
    "href": "http://stock.jrj.com.cn/2021/11/28163533929602.shtml",
    "datetime": "2021-11-28 16:35:38",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：38.94万股限制性股票可解锁",
    "href": "http://stock.jrj.com.cn/2021/11/25181233919689.shtml",
    "datetime": "2021-11-25 18:12:29",
    "code": "002821"
  },
  {
    "title": "追高加仓凯莱英（002821.SZ），顶级医药基金经理为何看好？",
    "href": "http://stock.jrj.com.cn/2021/11/22102533902606.shtml",
    "datetime": "2021-11-22 10:25:01",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：H股IPO通过港交所聆讯",
    "href": "http://stock.jrj.com.cn/2021/11/18075133870340.shtml",
    "datetime": "2021-11-18 07:51:57",
    "code": "002821"
  },
  {
    "title": "凯莱英拿下30亿大订单，明年业绩稳了？",
    "href": "http://stock.jrj.com.cn/2021/11/17125933865577.shtml",
    "datetime": "2021-11-17 12:59:41",
    "code": "002821"
  },
  {
    "title": "A股异动 | 凯莱英一字涨停 签订4.81亿美元CDMO服务合同",
    "href": "http://stock.jrj.com.cn/2021/11/17093033864462.shtml",
    "datetime": "2021-11-17 09:30:07",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：子公司签订4.809亿美元的相关产品新一批供货合同",
    "href": "http://stock.jrj.com.cn/2021/11/16200833861715.shtml",
    "datetime": "2021-11-16 20:08:13",
    "code": "002821"
  },
  {
    "title": "凯莱英：签订4.81亿美元CDMO服务合同",
    "href": "http://stock.jrj.com.cn/2021/11/16200533861705.shtml",
    "datetime": "2021-11-16 20:05:44",
    "code": "002821"
  },
  {
    "title": "凯莱英：香港联交所审议公司发行境外上市外资股申请",
    "href": "http://stock.jrj.com.cn/2021/11/12203033842503.shtml",
    "datetime": "2021-11-12 20:30:49",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：香港联交所上市委员会已审阅公司上市申请",
    "href": "http://stock.jrj.com.cn/2021/11/12195033842352.shtml",
    "datetime": "2021-11-12 19:50:44",
    "code": "002821"
  },
  {
    "title": "【龙虎榜】凯莱英11月8日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/11/08180233823865.shtml",
    "datetime": "2021-11-08 18:02:22",
    "code": "002821"
  },
  {
    "title": "凯莱英1.36亿溢价23倍收购医普科诺 三年业绩承诺3600万完善CRO布局",
    "href": "http://stock.jrj.com.cn/2021/10/26074133752401.shtml",
    "datetime": "2021-10-26 07:41:25",
    "code": "002821"
  },
  {
    "title": "凯莱英拟1.36亿元收购北京医普科诺 业绩对赌指标完成难度大",
    "href": "http://stock.jrj.com.cn/2021/10/25103633746148.shtml",
    "datetime": "2021-10-25 10:36:23",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：子公司近日收到专项补助资金784万元",
    "href": "http://stock.jrj.com.cn/2021/10/07185033646154.shtml",
    "datetime": "2021-10-07 18:50:58",
    "code": "002821"
  },
  {
    "title": "凯莱英：本次限制性股票上市流通日期为9月30日 占公司总股本0.0455%",
    "href": "http://stock.jrj.com.cn/2021/09/27182333525047.shtml",
    "datetime": "2021-09-27 18:23:11",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：11.122万股限制性股票9月30日解锁上市",
    "href": "http://stock.jrj.com.cn/2021/09/27165433524290.shtml",
    "datetime": "2021-09-27 16:54:45",
    "code": "002821"
  },
  {
    "title": "凯莱英2名股东合计减持2.2万股 套现合计957.25万 上半年公司净利4.29亿",
    "href": "http://stock.jrj.com.cn/2021/09/23222233506934.shtml",
    "datetime": "2021-09-23 22:22:44",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：高管陈朝勇、周炎已累计减持共4.4万股",
    "href": "http://stock.jrj.com.cn/2021/09/23210733506573.shtml",
    "datetime": "2021-09-23 21:07:36",
    "code": "002821"
  },
  {
    "title": "凯莱英：首次公开发行H股获中国证监会批复",
    "href": "http://stock.jrj.com.cn/2021/09/21173833487870.shtml",
    "datetime": "2021-09-21 17:38:34",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：港股IPO申请获得中国证监会批复",
    "href": "http://stock.jrj.com.cn/2021/09/21171033487789.shtml",
    "datetime": "2021-09-21 17:10:00",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：减持数过半 副总经理肖毅已减持2.26万股",
    "href": "http://stock.jrj.com.cn/2021/09/17215133453537.shtml",
    "datetime": "2021-09-17 21:51:54",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：副总经理陈朝勇减持量过半 累计减持1.07万股",
    "href": "http://stock.jrj.com.cn/2021/09/16182033446196.shtml",
    "datetime": "2021-09-16 18:20:47",
    "code": "002821"
  },
  {
    "title": "【龙虎榜】凯莱英9月6日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/09/06180333393309.shtml",
    "datetime": "2021-09-06 18:03:03",
    "code": "002821"
  },
  {
    "title": "凯莱英半年盈利4.29亿在手订单充沛 研发投入增长50.68%占比升至9.31%",
    "href": "http://stock.jrj.com.cn/2021/08/17074133264739.shtml",
    "datetime": "2021-08-17 07:41:56",
    "code": "002821"
  },
  {
    "title": "【龙虎榜】凯莱英8月16日成交明细",
    "href": "http://stock.jrj.com.cn/hotstock/2021/08/16180333261505.shtml",
    "datetime": "2021-08-16 18:03:21",
    "code": "002821"
  },
  {
    "title": "罕见跌停！业绩不及预期，惨遭高瓴抛弃的凯莱英还好吗？",
    "href": "http://stock.jrj.com.cn/2021/08/16154433260505.shtml",
    "datetime": "2021-08-16 15:44:09",
    "code": "002821"
  },
  {
    "title": "凯莱英跌停，上半年净利润同比增长36%，高瓴参与定增半年后减持逾220万股",
    "href": "http://stock.jrj.com.cn/2021/08/16103833258974.shtml",
    "datetime": "2021-08-16 10:38:28",
    "code": "002821"
  },
  {
    "title": "凯莱英2021年半年度净利4.29亿元 同比净利增加36.03%",
    "href": "http://stock.jrj.com.cn/2021/08/15214533254254.shtml",
    "datetime": "2021-08-15 21:45:09",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)半年度净利润4.29亿元 同比增长36.03%",
    "href": "http://stock.jrj.com.cn/2021/08/15164033253799.shtml",
    "datetime": "2021-08-15 16:40:03",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：拟向金融机构申请不超12亿元综合授信额度",
    "href": "http://stock.jrj.com.cn/2021/07/30195333176738.shtml",
    "datetime": "2021-07-30 19:53:34",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：拟使用不超5亿元部分闲置募集资金暂补流动资金",
    "href": "http://stock.jrj.com.cn/2021/07/30195233176737.shtml",
    "datetime": "2021-07-30 19:52:03",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)已向港交所递表",
    "href": "http://stock.jrj.com.cn/2021/06/29082433013950.shtml",
    "datetime": "2021-06-29 08:24:09",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：发行H股的申请材料获中证监受理",
    "href": "http://stock.jrj.com.cn/2021/06/28201733011668.shtml",
    "datetime": "2021-06-28 20:17:29",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：拟授予限制性股票245.53万股",
    "href": "http://stock.jrj.com.cn/2021/06/17203332949441.shtml",
    "datetime": "2021-06-17 20:33:06",
    "code": "002821"
  },
  {
    "title": "凯莱英：公司目前暂不涉及疫苗研发业务",
    "href": "http://stock.jrj.com.cn/2021/06/17135132947089.shtml",
    "datetime": "2021-06-17 13:51:41",
    "code": "002821"
  },
  {
    "title": "A股异动 | 凯莱英(002821.SZ)大跌近7% 部分董事及高管减持",
    "href": "http://stock.jrj.com.cn/2021/06/16105332939491.shtml",
    "datetime": "2021-06-16 10:53:54",
    "code": "002821"
  },
  {
    "title": "凯莱英：2020年公司生物大分子CDMO业务板块已组建了核心团队完成了厂房及主要设备验证",
    "href": "http://stock.jrj.com.cn/2021/06/01181032858146.shtml",
    "datetime": "2021-06-01 18:10:36",
    "code": "002821"
  },
  {
    "title": "A股异动 | 凯莱英(002821.SZ)涨逾4% 融资客大举买入 券商唱多",
    "href": "http://stock.jrj.com.cn/2021/05/20140132786880.shtml",
    "datetime": "2021-05-20 14:01:02",
    "code": "002821"
  },
  {
    "title": "凯莱英：公司目前暂不涉及疫苗研发业务",
    "href": "http://stock.jrj.com.cn/2021/05/08173732717123.shtml",
    "datetime": "2021-05-08 17:37:56",
    "code": "002821"
  },
  {
    "title": "凯莱英2021年第一季度净利增长42.86% 交付订单增长",
    "href": "http://stock.jrj.com.cn/2021/04/24091932434615.shtml",
    "datetime": "2021-04-24 09:19:15",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：与法尔玛制药签署核酸药物API产能建设项目委托代建与运营合同",
    "href": "http://stock.jrj.com.cn/2021/04/22220932426094.shtml",
    "datetime": "2021-04-22 22:09:03",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)一季度净利润升42.86%至1.54亿元",
    "href": "http://stock.jrj.com.cn/2021/04/22220732426092.shtml",
    "datetime": "2021-04-22 22:07:14",
    "code": "002821"
  },
  {
    "title": "凯莱英跌2.35% 总市值695亿去年净利润7亿",
    "href": "http://stock.jrj.com.cn/2021/04/16161632386816.shtml",
    "datetime": "2021-04-16 16:16:00",
    "code": "002821"
  },
  {
    "title": "凯莱英2020年净利7.2亿同比增长30% 董事长HAOHONG薪酬209万",
    "href": "http://stock.jrj.com.cn/2021/04/16113832385373.shtml",
    "datetime": "2021-04-16 11:38:15",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：2020年度净利升30.37%至7.22亿元 拟10派6元",
    "href": "http://stock.jrj.com.cn/2021/04/15210932381736.shtml",
    "datetime": "2021-04-15 21:09:51",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：1017.8731万股限售股将解禁",
    "href": "http://stock.jrj.com.cn/2021/04/13205132366932.shtml",
    "datetime": "2021-04-13 20:51:34",
    "code": "002821"
  },
  {
    "title": "凯莱英：在夯实小分子CDMO成熟业务基础上布局化学合成大分子等多个维度新的业务板块",
    "href": "http://stock.jrj.com.cn/2021/03/22171132195247.shtml",
    "datetime": "2021-03-22 17:11:12",
    "code": "002821"
  },
  {
    "title": "[凯莱英]凯莱英获评“2020年生化生物企业优秀合作伙伴”",
    "href": "http://stock.jrj.com.cn/2021/01/26000031778304.shtml",
    "datetime": "2021-01-26 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]荣耀随行:凯莱英获和记黄埔医药授予“卓越合作伙伴”荣誉",
    "href": "http://stock.jrj.com.cn/2021/01/14000031692202.shtml",
    "datetime": "2021-01-14 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]牵手瑞博生物,凯莱英推动小核酸CDMO业务“热启动”,蓄力创新药发展新动能",
    "href": "http://stock.jrj.com.cn/2021/01/11000031669478.shtml",
    "datetime": "2021-01-11 00:00:00",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)拟20亿元投资绿色关键技术开发及产业化项目和合成大分子CDMO项目",
    "href": "http://stock.jrj.com.cn/2021/01/10165131662282.shtml",
    "datetime": "2021-01-10 16:51:45",
    "code": "002821"
  },
  {
    "title": "[凯莱英]恭贺和黄医药索凡替尼获批,凯莱英全流程服务赋能新药上市",
    "href": "http://stock.jrj.com.cn/2021/01/06000031641418.shtml",
    "datetime": "2021-01-06 00:00:00",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：参股子公司天津有济医药拟引入产业资本增资扩股",
    "href": "http://stock.jrj.com.cn/2020/12/22192831546940.shtml",
    "datetime": "2020-12-22 19:28:52",
    "code": "002821"
  },
  {
    "title": "凯莱英：拟在美国投资设立全资子公司 主要从事创新药CDMO研发服务",
    "href": "http://stock.jrj.com.cn/2020/12/10172531457190.shtml",
    "datetime": "2020-12-10 17:25:27",
    "code": "002821"
  },
  {
    "title": "[凯莱英]凯莱英董事长洪浩博士荣获“2019年度金牛企业领袖奖”",
    "href": "http://stock.jrj.com.cn/2020/11/30000031376619.shtml",
    "datetime": "2020-11-30 00:00:00",
    "code": "002821"
  },
  {
    "title": "凯莱英：下半年小分子CDMO业务的重心已由开拓订单转为订单交付",
    "href": "http://stock.jrj.com.cn/2020/11/25163431346628.shtml",
    "datetime": "2020-11-25 16:34:05",
    "code": "002821"
  },
  {
    "title": "A股异动 | 凯莱英(002821.SZ)跌6% 遭控股股东ALAB减持77.36万股",
    "href": "http://stock.jrj.com.cn/2020/11/18132331307083.shtml",
    "datetime": "2020-11-18 13:23:16",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：ALAB持股降至37.47%",
    "href": "http://stock.jrj.com.cn/2020/11/16201331294038.shtml",
    "datetime": "2020-11-16 20:13:41",
    "code": "002821"
  },
  {
    "title": "凯莱英：公司在上海金山建立了生物大分子研发实验室",
    "href": "http://stock.jrj.com.cn/2020/10/27184931143604.shtml",
    "datetime": "2020-10-27 18:49:25",
    "code": "002821"
  },
  {
    "title": "凯莱英前三季度净利5.06亿增长38.12% 营业成本减少",
    "href": "http://stock.jrj.com.cn/2020/10/26074731130504.shtml",
    "datetime": "2020-10-26 07:47:19",
    "code": "002821"
  },
  {
    "title": "凯莱英：前三季度实现净利5.06亿元 同比增长38.12%",
    "href": "http://stock.jrj.com.cn/2020/10/23204131118788.shtml",
    "datetime": "2020-10-23 20:41:39",
    "code": "002821"
  },
  {
    "title": "凯莱英定增募资23亿元到账 高瓴资本以每股227元高价参与显“真爱”",
    "href": "http://stock.jrj.com.cn/2020/10/22013531103903.shtml",
    "datetime": "2020-10-22 01:35:58",
    "code": "002821"
  },
  {
    "title": "[凯莱英]凯莱英荣膺“2020中国化药制药工业综合实力百强”“2020中国化药制药工业环保、绿色制药特设奖”",
    "href": "http://stock.jrj.com.cn/2020/10/19000031084131.shtml",
    "datetime": "2020-10-19 00:00:00",
    "code": "002821"
  },
  {
    "title": "凯莱英：披露定增报告书 高瓴资本获配440.53万股",
    "href": "http://stock.jrj.com.cn/2020/10/12211931034100.shtml",
    "datetime": "2020-10-12 21:19:11",
    "code": "002821"
  },
  {
    "title": "[凯莱英]凯莱英速度:凯莱英口服固体制剂进口生产线顺利投产",
    "href": "http://stock.jrj.com.cn/2020/09/30000030867703.shtml",
    "datetime": "2020-09-30 00:00:00",
    "code": "002821"
  },
  {
    "title": "凯莱英(002821.SZ)：拟出资3亿元在镇江设立全资子公司 主营小分子CDMO化学原料及原料药研发生产",
    "href": "http://stock.jrj.com.cn/2020/09/28191630854589.shtml",
    "datetime": "2020-09-28 19:16:06",
    "code": "002821"
  },
  {
    "title": "[凯莱英]制药工业4.0:凯莱英CSO James Gage分享连续性反应的经验及应用",
    "href": "http://stock.jrj.com.cn/2020/09/24000030824381.shtml",
    "datetime": "2020-09-24 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]喊出“挣传统工艺挣不到的钱”!他用20年布局构建一个制药工艺技术帝国",
    "href": "http://stock.jrj.com.cn/2020/09/24000030833069.shtml",
    "datetime": "2020-09-24 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]凯莱英《Org.Process Res. Dev.》刊文 半连续工艺大规模GMP生产碳青霉烯中间体",
    "href": "http://stock.jrj.com.cn/2020/09/15000030754425.shtml",
    "datetime": "2020-09-15 00:00:00",
    "code": "002821"
  },
  {
    "title": "凯莱英一站式服务净利6年增6倍 3000万外延并购强化CRO布局",
    "href": "http://stock.jrj.com.cn/2020/09/09071430708381.shtml",
    "datetime": "2020-09-09 07:14:44",
    "code": "002821"
  },
  {
    "title": "[凯莱英]凯莱英并购冠勤医药,CRO板块战略部署提速换挡",
    "href": "http://stock.jrj.com.cn/2020/09/08000030704536.shtml",
    "datetime": "2020-09-08 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]供应链生态圈建设:凯莱英首届供应商大会召开",
    "href": "http://stock.jrj.com.cn/2020/09/08000030704534.shtml",
    "datetime": "2020-09-08 00:00:00",
    "code": "002821"
  },
  {
    "title": "凯莱英以自有资金3000万收购冠勤医药原股东持有的100%股权",
    "href": "http://stock.jrj.com.cn/2020/09/07192630695015.shtml",
    "datetime": "2020-09-07 19:26:05",
    "code": "002821"
  },
  {
    "title": "[凯莱英]凯莱英与Snapdragon Chemistry达成投资合作,携手制药生产革命性新技术开发与应用",
    "href": "http://stock.jrj.com.cn/2020/09/01000030653744.shtml",
    "datetime": "2020-09-01 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]凯莱英RA团队护航药品全生命周期一站式综合服务",
    "href": "http://stock.jrj.com.cn/2020/08/25000030603405.shtml",
    "datetime": "2020-08-25 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]2019年度中国医药行业最具影响力榜单震撼发布,凯莱英荣获四项大奖",
    "href": "http://stock.jrj.com.cn/2020/08/25000030603404.shtml",
    "datetime": "2020-08-25 00:00:00",
    "code": "002821"
  },
  {
    "title": "凯莱英一度拉涨8%！半年度净利润增加37%",
    "href": "http://stock.jrj.com.cn/2020/08/10094330463669.shtml",
    "datetime": "2020-08-10 09:43:14",
    "code": "002821"
  },
  {
    "title": "凯莱英2020年上半年净利3.16亿增长37.63% CDMO订单持续增长",
    "href": "http://stock.jrj.com.cn/2020/08/07235230452610.shtml",
    "datetime": "2020-08-07 23:52:09",
    "code": "002821"
  },
  {
    "title": "凯莱英定增高瓴靠边站 兴全等公募抬轿子让私募套利？",
    "href": "http://stock.jrj.com.cn/2020/07/24070630329306.shtml",
    "datetime": "2020-07-24 07:06:00",
    "code": "002821"
  },
  {
    "title": "国务院印发《深化医药卫生体制改革2020年下半年重点工作任务》 凯莱英23亿定增方案生变 | 医资日报",
    "href": "http://stock.jrj.com.cn/2020/07/23183030325398.shtml",
    "datetime": "2020-07-23 18:30:17",
    "code": "002821"
  },
  {
    "title": "战投式定增被按“暂停键”！高瓴资本或无缘凯莱英战略投资者，浮盈变浮云，盛宴提前散了",
    "href": "http://stock.jrj.com.cn/2020/07/23081830320356.shtml",
    "datetime": "2020-07-23 08:18:09",
    "code": "002821"
  },
  {
    "title": "凯莱英修改定增方案 战投定价发行有变？",
    "href": "http://stock.jrj.com.cn/2020/07/23025430318155.shtml",
    "datetime": "2020-07-23 02:54:43",
    "code": "002821"
  },
  {
    "title": "[凯莱英]互联网+大健康,一体两翼惠民生:凯莱英与泰心医院系列签约仪式在津举行",
    "href": "http://stock.jrj.com.cn/2020/07/04000030146905.shtml",
    "datetime": "2020-07-04 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]【重磅】从临床到商业化:凯莱英与贝达药业全面深化战略合作",
    "href": "http://stock.jrj.com.cn/2020/07/01000030110224.shtml",
    "datetime": "2020-07-01 00:00:00",
    "code": "002821"
  },
  {
    "title": "凯莱英公司点评：公布2020年激励计划 长期发展值得期待",
    "href": "http://stock.jrj.com.cn/2020/06/30123930095912.shtml",
    "datetime": "2020-06-30 12:39:09",
    "code": "002821"
  },
  {
    "title": "凯莱英聘任姜英伟为公司副总经理",
    "href": "http://stock.jrj.com.cn/2020/06/24204030012142.shtml",
    "datetime": "2020-06-24 20:40:16",
    "code": "002821"
  },
  {
    "title": "凯莱英4名高级管理人员拟减持股份 预计合计减持不超总股本0.04%",
    "href": "http://stock.jrj.com.cn/2020/06/17214029951619.shtml",
    "datetime": "2020-06-17 21:40:52",
    "code": "002821"
  },
  {
    "title": "[凯莱英]凯莱英加速布局创新药全产业链服务能力,新项目落户镇江经开区",
    "href": "http://stock.jrj.com.cn/2020/06/03000030080766.shtml",
    "datetime": "2020-06-03 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]技术驱动发展:凯莱英升级CEPS、CED、CMMD多个技术平台,加速释放连续反应等核心竞争力",
    "href": "http://stock.jrj.com.cn/2020/05/26000030080764.shtml",
    "datetime": "2020-05-26 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]【纪实】凯莱英携手天津市药监局共建“天津市药品监管实训基地”",
    "href": "http://stock.jrj.com.cn/2020/05/22000030080757.shtml",
    "datetime": "2020-05-22 00:00:00",
    "code": "002821"
  },
  {
    "title": "凯莱英与辉瑞等制药巨头嵌入式合作 引入战投高瓴锁定至少8亿订单",
    "href": "http://stock.jrj.com.cn/2020/05/14075329667452.shtml",
    "datetime": "2020-05-14 07:53:19",
    "code": "002821"
  },
  {
    "title": "凭啥担当凯莱英战投？高瓴资本：“不带来8亿元订单不减持”",
    "href": "http://stock.jrj.com.cn/2020/05/14074529667314.shtml",
    "datetime": "2020-05-14 07:45:06",
    "code": "002821"
  },
  {
    "title": "高瓴狂砸27亿 两股应声暴涨 最高近涨停！更“送”这公司至少8亿订单",
    "href": "http://stock.jrj.com.cn/2020/05/13125429659364.shtml",
    "datetime": "2020-05-13 12:54:35",
    "code": "002821"
  },
  {
    "title": "高瓴又出手！与这家公司达成战略合作 还承诺带来至少8亿订单！股价果然有反应...",
    "href": "http://stock.jrj.com.cn/2020/05/13124329659337.shtml",
    "datetime": "2020-05-13 12:43:00",
    "code": "002821"
  },
  {
    "title": "高瓴资本与凯莱英达成战略合作 并承诺为凯莱英带来至少8亿元订单",
    "href": "http://stock.jrj.com.cn/2020/05/13094629658116.shtml",
    "datetime": "2020-05-13 09:46:01",
    "code": "002821"
  },
  {
    "title": "[凯莱英]凯莱英速度:攻坚克难,注射剂车间多个生产项目顺利完成",
    "href": "http://stock.jrj.com.cn/2020/05/13000030080762.shtml",
    "datetime": "2020-05-13 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]凯莱英天津子公司建设项目二期工程全面启动建设",
    "href": "http://stock.jrj.com.cn/2020/04/29000030080761.shtml",
    "datetime": "2020-04-29 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]创新,变革:开创性院企合作赋能新药上市,凯莱英牵手泰心共建TICCR滨海中心",
    "href": "http://stock.jrj.com.cn/2020/04/17000030080760.shtml",
    "datetime": "2020-04-17 00:00:00",
    "code": "002821"
  },
  {
    "title": "凯莱英：2019年净利同比增长29.32%",
    "href": "http://stock.jrj.com.cn/2020/04/09102629244003.shtml",
    "datetime": "2020-04-09 10:26:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]高通量筛选与AI辅助进化平台——让凯莱英生物酶催化技术“如虎添翼”",
    "href": "http://stock.jrj.com.cn/2020/03/27000029348262.shtml",
    "datetime": "2020-03-27 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]高通量筛选与AI辅助进化平台——让凯莱英生物酶催化技术“如虎添翼”",
    "href": "http://stock.jrj.com.cn/2020/03/27000030080756.shtml",
    "datetime": "2020-03-27 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]中国第一颗“人造心脏”助两位患者生命延续,转眼一周年",
    "href": "http://stock.jrj.com.cn/2020/03/17000029043437.shtml",
    "datetime": "2020-03-17 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]绿色创新技术︱第三代抗菌增效剂他唑巴坦连续合成工艺开发",
    "href": "http://stock.jrj.com.cn/2020/03/12000030080755.shtml",
    "datetime": "2020-03-12 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]泰达温度:天津经开区政府强化两“战”并重,有力支持凯莱英复工复产",
    "href": "http://stock.jrj.com.cn/2020/03/03000030080759.shtml",
    "datetime": "2020-03-03 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]市委常委、市委统战部部长冀国强深入凯莱英调研视察,推动企业复工复产",
    "href": "http://stock.jrj.com.cn/2020/03/03000028946552.shtml",
    "datetime": "2020-03-03 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]市委常委、市委统战部部长冀国强深入凯莱英调研视察,推动企业复工复产",
    "href": "http://stock.jrj.com.cn/2020/03/03000030080765.shtml",
    "datetime": "2020-03-03 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]泰达温度:天津经开区政府强化两“战”并重,有力支持凯莱英复工复产",
    "href": "http://stock.jrj.com.cn/2020/03/03000028946553.shtml",
    "datetime": "2020-03-03 00:00:00",
    "code": "002821"
  },
  {
    "title": "凯莱英2019年盈利5.56亿元增长30% 小分子业务持续快速增长",
    "href": "http://stock.jrj.com.cn/2020/02/29130228919431.shtml",
    "datetime": "2020-02-29 13:02:12",
    "code": "002821"
  },
  {
    "title": "凯莱英：2019年净利5.56亿元 同比增长30%",
    "href": "http://stock.jrj.com.cn/2020/02/28182628915984.shtml",
    "datetime": "2020-02-28 18:26:26",
    "code": "002821"
  },
  {
    "title": "再融资新规“红利”价值凸显 高瓴资本八折入手凯莱英持股升至8%",
    "href": "http://stock.jrj.com.cn/2020/02/18073328845610.shtml",
    "datetime": "2020-02-18 07:33:23",
    "code": "002821"
  },
  {
    "title": "[凯莱英]做时间的朋友:高瓴携手凯莱英开启全面战略合作",
    "href": "http://stock.jrj.com.cn/2020/02/18000028859772.shtml",
    "datetime": "2020-02-18 00:00:00",
    "code": "002821"
  },
  {
    "title": "高瓴携手凯莱英开启全面战略合作",
    "href": "http://stock.jrj.com.cn/2020/02/17220128841382.shtml",
    "datetime": "2020-02-17 22:01:00",
    "code": "002821"
  },
  {
    "title": "高瓴资本8折独吞凯莱英23亿元定增 这个“卖铲子”的行业为何让资本汹涌而至？",
    "href": "http://stock.jrj.com.cn/2020/02/17211528841185.shtml",
    "datetime": "2020-02-17 21:15:15",
    "code": "002821"
  },
  {
    "title": "凯莱英：高瓴资本拟认购1870万股 持股升至8%",
    "href": "http://stock.jrj.com.cn/2020/02/17193528840794.shtml",
    "datetime": "2020-02-17 19:35:00",
    "code": "002821"
  },
  {
    "title": "凯莱英：高瓴资本拟认购1870万股 持股比例将升至8%",
    "href": "http://stock.jrj.com.cn/2020/02/17191628840655.shtml",
    "datetime": "2020-02-17 19:16:00",
    "code": "002821"
  },
  {
    "title": "凯莱英：高瓴资本拟认购公司非公开发行的全部1870万股",
    "href": "http://stock.jrj.com.cn/2020/02/17183928840206.shtml",
    "datetime": "2020-02-17 18:39:21",
    "code": "002821"
  },
  {
    "title": "再融资新规落地 凯莱英等3家公司因推新版融资方案股价涨停",
    "href": "http://stock.jrj.com.cn/2020/02/17094428836917.shtml",
    "datetime": "2020-02-17 09:44:27",
    "code": "002821"
  },
  {
    "title": "再融资新规落地 凯莱英等多股闪推新方案",
    "href": "http://stock.jrj.com.cn/2020/02/17020528835725.shtml",
    "datetime": "2020-02-17 02:05:28",
    "code": "002821"
  },
  {
    "title": "[凯莱英]酶工程技术案例︱“升级改造”单加氧酶,高效催化手性亚砜",
    "href": "http://stock.jrj.com.cn/2020/02/17000029358073.shtml",
    "datetime": "2020-02-17 00:00:00",
    "code": "002821"
  },
  {
    "title": "23亿全额拿下凯莱英定增 高瓴助力中国高质量医药制造",
    "href": "http://stock.jrj.com.cn/2020/02/16223728835464.shtml",
    "datetime": "2020-02-16 22:37:56",
    "code": "002821"
  },
  {
    "title": "高瓴资本75折认购凯莱英背后：美股布局创新药 A股布局CRO",
    "href": "http://stock.jrj.com.cn/2020/02/16204028835303.shtml",
    "datetime": "2020-02-16 20:40:38",
    "code": "002821"
  },
  {
    "title": "公告精选：凯莱英等多家推新版融资方案",
    "href": "http://stock.jrj.com.cn/2020/02/16195028835213.shtml",
    "datetime": "2020-02-16 19:50:00",
    "code": "002821"
  },
  {
    "title": "凯莱英推新版融资方案 高瓴资本战略入股",
    "href": "http://stock.jrj.com.cn/2020/02/16185928835083.shtml",
    "datetime": "2020-02-16 18:59:00",
    "code": "002821"
  },
  {
    "title": "凯莱英推新版融资方案：拟募资不超23.11亿元 高瓴资本全额认购",
    "href": "http://stock.jrj.com.cn/2020/02/16174428834863.shtml",
    "datetime": "2020-02-16 17:44:07",
    "code": "002821"
  },
  {
    "title": "凯莱英推新版融资方案：拟募资不超23.11亿元 高瓴资本全额认购",
    "href": "http://stock.jrj.com.cn/2020/02/16173428834857.shtml",
    "datetime": "2020-02-16 17:34:00",
    "code": "002821"
  },
  {
    "title": "凯莱英：各研发生产基地陆续复工复产",
    "href": "http://stock.jrj.com.cn/2020/02/14214928831613.shtml",
    "datetime": "2020-02-14 21:49:00",
    "code": "002821"
  },
  {
    "title": "凯莱英：各研发生产基地已有序复工复产",
    "href": "http://stock.jrj.com.cn/2020/02/14105828828565.shtml",
    "datetime": "2020-02-14 10:58:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]有爱,便千难无碍:凯莱英子公司向吉林省敦化市政府捐赠防疫物资,共克时艰",
    "href": "http://stock.jrj.com.cn/2020/02/11000028827263.shtml",
    "datetime": "2020-02-11 00:00:00",
    "code": "002821"
  },
  {
    "title": "凯莱英：公司及创始人捐赠善款和急需的医用设备合计300万元",
    "href": "http://stock.jrj.com.cn/2020/02/01153928747009.shtml",
    "datetime": "2020-02-01 15:39:00",
    "code": "002821"
  },
  {
    "title": "凯莱英捐款300万元用于抗击疫情",
    "href": "http://stock.jrj.com.cn/2020/01/31141928745020.shtml",
    "datetime": "2020-01-31 14:19:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]有爱,便千难无碍:凯莱英以实际行动映射国人温暖底色",
    "href": "http://stock.jrj.com.cn/2020/01/30000028752822.shtml",
    "datetime": "2020-01-30 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]颠覆传统,“筑”力创新︱凯莱英构建乙炔基格氏试剂连续生产平台",
    "href": "http://stock.jrj.com.cn/2020/01/21000029340896.shtml",
    "datetime": "2020-01-21 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]创新聚变,再启新篇:凯莱英2020新帆起航",
    "href": "http://stock.jrj.com.cn/2020/01/14000028678464.shtml",
    "datetime": "2020-01-14 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]凯莱英合作伙伴再鼎医药PARP 抑制剂「则乐」上市",
    "href": "http://stock.jrj.com.cn/2020/01/14000028678463.shtml",
    "datetime": "2020-01-14 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]海外高层次青年人才到访凯莱英参观考察",
    "href": "http://stock.jrj.com.cn/2020/01/13000028678461.shtml",
    "datetime": "2020-01-13 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]“羽”我同行 “羽”你同在 ——凯莱英天津公司羽毛球比赛圆满落幕",
    "href": "http://stock.jrj.com.cn/2020/01/11000028678460.shtml",
    "datetime": "2020-01-11 00:00:00",
    "code": "002821"
  },
  {
    "title": "[凯莱英]创新赋能发展,加速药品上市:“浦江之夜”创新药发展之NDA与 MAH策略论坛召开",
    "href": "http://stock.jrj.com.cn/2019/12/19000028556044.shtml",
    "datetime": "2019-12-19 00:00:00",
    "code": "002821"
  }
]